NCT01818479终止1 期
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Rate of acute GVHD
研究概览
简要总结
Open label, dose finding trial to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells. The maximum tolerated dose will be established using 3 subjects per dose level, with an expansion cohort at the maximum tolerated dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 0-70 years
- •Karnofsky or Lansky Performance status >70%
- •High risk hematologic malignancy
- •Acute myeloid leukemia (AML) with one or more of the following criteria: 4a.Poor risk cytogenetics, including -5, 5q-, -7, 7q-, t(9;22); complex cytogenetics (>3 abnormalities); or normal cytogenetics with Flt3 internal tandem duplication (ITD), in first or subsequent complete remission (CR).
- •4b. Relapsed or primary refractory AML with <10% blasts in the peripheral blood.
- •4c. Subjects in first complete remission (CR1) who required two cycles of induction to achieve remission may be included at the discretion of the treating physician.
- •4d. Standard risk or intermediate risk cytogenetics in second or subsequent CR (enrolled at the discretion of the treating physician).
- •Acute lymphoblastic leukemia (ALL) with one of the following criteria: 5a. Second or subsequent CR 5b. Any partial remission (PR) (no circulating blasts) 5c. High-risk ALL in first CR including (Ph+, t(4:11), complex karyotype, hypodiploidy (<44 chromosomes), or positive minimal residual disease (MRD) after induction
- •Myelodysplasia, intermediate -2 (score 1.5-2.0) or high risk (score >2.5) by the International Prognostic Score System.
- •Myeloproliferative Disorders (include chronic myelomonocytic leukemia (CMML), agnogenic myeloid metaplasia (AMM) or Idiopathic Myelofibrosis, and JMML) with excess blasts (>5%)
- •Chronic myeloid leukemia (CML) with one of the following criteria: 8a. Second or subsequent chronic phase 8b. Accelerated phase 8c. blast crisis
- •Non-Hodgkin's lymphoma (NHL) meeting one of the following criteria: 9a. Relapse after autologous stem cell transplantation with evidence of responsive disease.
- •9b. Subject with chemosensitive relapse who have no option for autologous stem cell transplantation due to blood or marrow involvement or failure to mobilize autologous stem cells or are not considered eligible for autologous transplant by their treating physician.
- •9c. Hodgkin's Lymphoma: relapse after autologous hematopoietic cell transplantation (HCT), chemo-refractory disease 9d. Multiple myeloma: per National Comprehensive Cancer Network (NCCN) guidelines. Updated annually at: www.nccn.org
- •No suitable human leukocyte antigen (HLA)-identical sibling donor.
- •No identified 8/8 (based upon A, B, C, DR beta 1 (DRB1) loci) allele matched unrelated donor, or unable to wait sufficient time to procure a 8/8 allele matched unrelated donor
- •Available HLA 3-5/6 matched genotypically haploidentical partially matched related donor
- •Female subjects must be surgically sterile, postmenopausal (minimum 1 year without menses), or agree to use approved form of contraception from the time of signing the informed consent form through Day +
- •Male subjects must also agree to use an approved form of birth control for either themselves or their partner, as appropriate, from the time of signing the informed consent form through Day +
- •Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.
排除标准
- •Available HLA identical matched sibling donor (unless having failed a prior allogeneic transplant from an HLA identical matched sibling)
- •Recipient HLA antibodies against donor HLA
- •Any of the following organ dysfunctions:
- •Cardiac- left ventricular ejection fraction <40%, symptomatic coronary artery disease, or uncontrolled arrhythmias
- •Pulmonary- forced expiratory volume at one second (FEV1) or diffusion capacity of lung for carbon monoxide (DLco)<40% or need for use of supplemental oxygen
- •Renal- calculated or measured glomerular filtration rate (GFR) <30 ml/min, dialysis requirement, or prior renal transplant
- •Hepatic- bilirubin > 2.0, alanine aminotransferase (ALT) > 2.5 X upper limit of normal (ULN), cirrhosis
- •Subjects with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
- •Subjects who have tested positive for HIV.
- •Pregnant women, nursing mothers or women of child-bearing potential who are unwilling to use medically accepted methods of contraception.
结局指标
主要结局
Rate of acute GVHD
时间窗: 36 months
Rate of acute Graft Versus Host Disease (GVHD) grade III-IV at Day +100 post transplant
次要结局
- Rate of Engraftment(36 months)
- Survival at Day 100(36 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of TRC102 in Combination With Pemetrexed in Cancer PatientsNeoplasmNCT00692159Tracon Pharmaceuticals Inc.28
已完成
2 期
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02983617Gilead Sciences36
已完成
2 期
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02968563Gilead Sciences35
已完成
1 期
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed GlioblastomaGlioblastomaGliomaGBMNCT01465347Diffusion Pharmaceuticals Inc59
已完成
2 期
Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant TacrolimusInterstitial PneumonitisPolymyositisDermatomyositisNCT00504348Tokyo Medical and Dental University25